<DOC>
	<DOCNO>NCT01767948</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics ( drug concentration change time ) PCI 32765 participant mild , moderate , severe hepatic impairment .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetics PCI-32765 Participants With Varying Degrees Hepatic Impairment</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , single-dose , multi-center ( study conduct multiple site ) , non-randomized study access pharmacokinetics PCI-32765 participant either mild , moderate , severe hepatic impairment qualify control group ( normal liver function ) . The study mainly consist 3 phase : screening phase ( within 21 day prior first dose study medication ) , treatment phase , follow phase ( 10 12 day last dose study medication ) . In treatment phase , participant receive single oral dose PCI-32765 Day 1 . Liver impairment classify accord Child-Pugh Classification Severity Liver Disease , : normal , mild , moderate , severe . Total 30 participant ( 24 hepatic impairment [ 6 mild , 9 moderate 9 severe ] baseline 6 control group accord Child-Pugh criterion ) enrol . Participants control group enrol participant mild moderate hepatic impairment complete study . Safety evaluation adverse event , clinical laboratory test , electrocardiogram , vital sign , physical examination monitor throughout study . The total duration study participant approximately 29 33 day .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Stable hepatic function confirm serum bilirubin transaminase level measure screening measure within 48 hour prior PCI32765 administration Must hepatically impair define ChildPugh classification severity liver disease Control group must good health normal liver function Participants control hypertension problem directly associate primary diagnosis hepatic impairment Concomitant medication treat underlying disease state medical condition relate hepatic impairment allow Agrees protocoldefined use effective contraception Clinically significant renal laboratory finding include serum creatinine 1.5 x upper limit normal ( ULN ) and/or calculate creatinine clearance le 60 ml per minute per 1.73 square meter Clinically significant abnormal laboratory test , physical examination , vital sign electrocardiogram screen admission study center Antiviral therapy active hepatitis infection time screen Use anticoagulation therapy include vitamin K antagonist , low molecular weight heparin , anticoagulant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Hepatic Impairment</keyword>
	<keyword>PCI 32765</keyword>
	<keyword>Metabolite PCI-45227</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>